Is t(11;14) in newly diagnosed multiple myeloma a favorable outcome in the novel agent era?
In this study, patients with MM with t(11;14) demonstrated poorer PFS than those with normal cytogenetics. Further investigations are required to evaluate the impact of t(11;14) in patients newly diagnosed with MM in the era of novel agents.
Authors
- Yuan Jian (ORCID: https://orcid.org/0000-0003-4833-415X)
- Jingjing Deng (ORCID: https://orcid.org/0000-0002-8457-4380)
- Li Ye (ORCID: https://orcid.org/0000-0002-9246-5520)
- Wenming Chen (ORCID: https://orcid.org/0000-0001-6298-8489)
- Zhiyao Zhang (ORCID: https://orcid.org/0000-0002-6974-373X)
Institutions
- Capital Medical University (CN)
- Peking University (CN)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Peking University People's Hospital (CN)
- Beijing Chaoyang Emergency Medical Center (CN)
Publication Details
- Journal
- Blood Research
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1007/s44313-025-00056-8
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77